| 摘要 |
PCT No. PCT/GB95/02992 Sec. 371 Date Jun. 24, 1997 Sec. 102(e) Date Jun. 24, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20216 PCT Pub. Date Jul. 4, 1996Cyclic peptides of formula (1): Wherein: AA1 is an +E,uns L+EE or +E,uns D+EE amino acid selected from Ile and Leu or amino acid analogue thereof; AA2 is an +E,uns L+EE amino acid selected from Leu or amino acids analogue thereof; AA3 is an +E,uns L+EE amino acid selected from Asp or amino acid analogue thereof containing a carboxy group in its side chain; AA4 is an +E,uns L+EE amino acid selected from Val or amino acid analogue thereof and; LINKER represents a linking moiety for linking N terminus of AA1 to C terminus of AA4 to form a cyclic peptide containing a heterocyclic ring having 17 to 30 members. The cyclic peptides inhibit the interaction of vascular cell adhesion molecule-1 and fibronectin with integrin very late antigen 4 and have therapeutic applications such as in rheumatoid arthritis or multiple sclerosis. |
